Beta blockers for peripheral arterial disease

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 9, 2013, Pages

  Paravastu, Sharath Chandra Vikram ^a   Mendonca, Derick A ^b   Da Silva, Anthony ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Bangalore Baptist Hospital   (India)

^c WREXHAM MAELOR HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; METOPROLOL; PINDOLOL; PLACEBO; PROPRANOLOL;

ARTERIAL SMOOTH MUSCLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL OUTCOME; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; GASTROCNEMIUS MUSCLE; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; ISCHEMIA; LEG BLOOD FLOW; MUSCLE BLOOD FLOW; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL CAPACITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN TEMPERATURE; SMOOTH MUSCLE RELAXATION; SYMPTOM; SYSTEMATIC REVIEW; TREADMILL TEST; TREATMENT RESPONSE; VASCULAR RESISTANCE; WALKING; BLOOD FLOW; DRUG EFFECT; PERIPHERAL VASCULAR DISEASE; DRUG EFFECTS; PERIPHERAL VASCULAR DISEASES;

ADRENERGIC BETA-ANTAGONISTS; ATENOLOL; HUMANS; INTERMITTENT CLAUDICATION; METOPROLOL; PERIPHERAL VASCULAR DISEASES; PINDOLOL; PROPRANOLOL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGIONAL BLOOD FLOW; WALKING;

EID: 84898726916     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005508.pub3     Document Type: Review

References (54)

1. Bogaert MG, Clement DL. Lack of influence of propranolol and metoprolol on walking distance in patients with chronic intermittent claudication. European Heart Journal 1983;4(3):203-4.
2. Clement DL. Studies on the effect of alpha-and beta-adrenergic blocking agents on the circulation in human limbs. Verhandelingen Van De Koninklijke Academie voor Geneeskunde van Belgie 1980;XLII(3-4)(42):164-214.
3. Hiatt WR, Stoll S, Nies AS. Effect of beta-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease. Circulation 1985;72(6):1226-31.
4. Lepantalo M. Chronic effects of metoprolol and methyldopa on calf blood flow in intermittent claudication. British Journal of Clinical Pharmacology 1984;18(1):90-3.
5. Lepantalo M. Chronic effects of labetalol, pindolol, and propranolol on calf blood flow in intermittent claudication. Clinical Pharmacology and Therapeutics 1985;37(1):7-12.
6. Lepantalo M, Lindstorm BL, Totterman KJ. Adrenoreceptor blocking drugs and cold feet in intermittent claudication. VASA. Zeitschrift für Gefässkrankheiten 1986;15(2):135-7.
7. Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A. Placebo controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet 1987;ii:(8560):650-3.
8. Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. Beta-blockade and intermittent claudication: placebo controlled trial of atenolol, nifedipine and their combination. BMJ 1991;303(6810):1100-4.
9. Aarts PA, Banga JD, van Houwelingen HC, Heethaar RM, Sixma JJ. Increased red blood cell deformability due to isoxsuprine administration decreases platelet adherence in a perfusion chamber: a double-blind cross-over study in patients with intermittent claudication. Blood 1986;67(5):1474-81.
10. Bostrom PA, Janzon L, Ohlsson O, Westergren A. The effect of beta-blockade on leg blood flow in hypertensive patients with intermittent claudication. Angiology 1986;37(3 pt1):149-53.
11. Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Journal of Hypertension 1998;16(12):2113-6. [MEDLINE: 4769]
12. Diehm C, Jacobsen O, Amendt K. The effects of tertalolol on lipid profile. Cardiology 1993;83 Suppl 1:32-40.
13. Diehm C, Pittrow D, Lawall H. Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. Journal of Hypertension 2011;29:1448-56.
14. Ehrly AM, Landgraf H, Saeger LK. Influence of propranolol and bunitrolol on muscular tissue oxygen pressure of patients with intermittent claudication and arterial hypertension. Die Medizinische Welt 1987;38:1052-5.
15. Espinola-Klein C, Weisser G, Jagodzinski A, Savvidis S, Warnholtz A, Ostad MA, et al.Beta-blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension 2011;58(2):148-54.
16. Forbes CD, Lowe GD, Maclaren M, Shaw BG, Dickinson JP, Keiffer G. Clopidogrel compatibility with concomitant cardiac co-medications: a study of its interactions with a beta blocker and a calcium uptake antagonist. Seminars in Thrombosis and Hemostasis 1999;25 Suppl 2:55-60.
17. Iarussi D, Ferrante MR, Garofalo S, De Cristofaro M. Instrumental evaluation of the effects of a delayed-action preparation of a isoxsuprine on the peripheral circulation [Valutazione strumentale degli effetti sul circolo periferico di un preparato di isossisuprina ad azione protratta]. La Clinica Terapeutica 1977;80(4):315-25.
18. Karnik R, Valentin A, Slany J. Different effects of beta-1-adrenergic blocking agents with ISA or without ISA on peripheral blood flow. Angiology 1987;38(4):296-303.
19. Klieber M, Resch F. Comparative studies of the effect of a cardioselective and a non-cardioselective beta blocker on peripheral circulation in patients with arterial occlusive disease. Wiener Klinische Wochenschrift 1986;98(3):70-3.
20. Konecny U, Ehringer H, Rasser W, Koppensteiner R, Minar E, Wachter M. The acute effect of celiprolol I.V. on the resting blood flow of calf and foot in healthy subjects and patients with peripheral arterial occlusive disease (PAOD). What is new in angiology? Trends and controversies. Zuckschwerdt W, 1986:541-2.
21. Lepantalo M, von Knorring J. Walking capacity of patients with intermittent claudication during chronic antihypertensive treatment with metoprolol and methyldopa. Clinical Physiology 1984;4(4):275-82.
22. Novo S, Pinto A, Galati D, Giannola A, Forte G, Strano A. Effects of chronic administration of selective beta blockers on peripheral circulation of lower limbs in patients with essential hypertension. International Angiology 1985;4(2):229-34.
23. Novo S, Alaimo G, Abrignani MG, Giordano U, Avellone G, Pinto A, et al.Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arterioscleorosis obliterans of the lower limb. International Journal of Clinical and Pharmacology Research 1986;6(3):199-211.
24. Reichert N, Shibolet S, Adar R, Gafni J. Controlled trial of propranolol in intermittent claudication. Clinical Pharmacology and Therapeutics 1975;17(5):612-5.
25. Schweizer J, Kaulen R, Altmann E, Nierade A, Nanning T. Are beta-blockers generally contraindicated in patients with peripheral arterial occlusive disease?. Zeitschrift fur Kardiologie 1996;85(3):193-7.
26. Schweizer J, Kaulen R, Nierade A, Altmann E. Beta-blockers and nitrates in patients with peripheral arterial occlusive disease: long-term findings. VASA. Zeitschrift für Gefässkrankheiten 1997;26(1):43-6.
27. Skotnicki SH, van Gaal G, Wijn PF. The effectiveness of Isoxsuprine in patients with intermittent claudication. Angiology 1984;35(11):685-93.
28. Smith RS, Warren DJ. Effect of beta-blocking drugs on peripheral blood flow in intermittent claudication. Journal of Cardiovascular Pharmacology 1982;4(1):2-4.
29. Strandness D Jr. Ineffectiveness of isoxsuprine on intermittent claudication. JAMA 1970;213(1):86-8.
30. Svendsen TL, Jelnes R, Tonnesen KH. Is adrenergic beta receptor blockade contraindicated in patients with intermittent claudication. Acta Medica Scandinavica 1985;693:129-32.
31. Svendsen TL, Jelnes R, Tonnesen KH. The effects of acebutolol and metoprolol on walking distances and distal blood pressure in hypertensive patients with intermittent claudication. Acta Medica Scandinavica 1986;219(2):161-5.
32. van de Ven LL, van Leeuwen JT, Smit AJ. The influence of chronic treatment with beta blockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial. VASA. Zeitschrift für Gefässkrankheiten 1994;23(4):357-62.
33. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al.2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of American College of Cardiology 2013; Vol. 61, issue 23:e179 -347.
34. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94, 492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. American Journal of Cardiology 2007;100(8):1254-62.
35. Joint Formulary Committee. British National Formulary. Vol. 65, London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2013.
36. Chen JMH, Heran BS, Perez MI, Wright JM. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD007185.pub2]
37. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71(3):510-5.
38. George CF. Beta-receptor blocking agents. Prescribers Journal 1974;14:93-8.
39. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. New England Journal of Medicine 2001;344(21):1608-21.
40. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org. The Cochrane Collaboration.
41. Hughson WG, Mann JI, Garrod A. Intermittent claudication: prevalence and risk factors. British Medical Journal 1978;1(6124):1379-81.
42. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomised clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
43. Javed U, Deedwania PC. Beta-adrenergic blockers for chronic heart failure. Cardiology in Review 2009;17(6):287-92.
44. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. Journal of the American Geriatrics Society 1985;33(1):13-8.
45. Lassila R, Lepantalo M, Lindfors O. Peripheral arterial diseasenatural outcome. Acta Medica Scandinavica 1986;220(4):295-301.
46. Lavie CJ, Messerli FH, Milani RV. Beta-blockers as first-line antihypertensive therapy: the crumbling continues. Journal of the American College of Cardiology 2009;54(13):1162-4.
47. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366(9496):1545-53.
48. MIAMI Trial Researchers. Metoprolol in acute myocardial infarction. Other clinical findings and tolerability. The MIAMI Trial Research Group. American Journal of Cardiology 1985;56(14):G39-G46.
49. Miyajima R, Sano K, Yoshida H. Beta-adrenergic blocking agents and intermittent claudication: systematic review. Yakugaku Zasshi 2004;124(11):825-31.
50. NICE. Chronic heart failure: management of chronic heart failure in adults in primary and secondary care. Clinical guidelines CG108: August 2010 Issue. www.nice.org.uk (accessed 7 August 2013).
51. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
52. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al.Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD002003.pub2]
53. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2]
54. Paravastu SCV, Mendonca D, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD005508.pub2]